Statement by the Board of Directors of Meda in relation to Mylan, Inc.

This statement is made by the Board of Directors (the ”Board”) of Meda AB (publ)
(”Meda”) pursuant to the Securities Markets Act and//or the Financial
Instruments Trading Act.

The Board hereby confirms that it has been contacted by Mylan, Inc. (“Mylan”)
regarding a revised non-binding indicative interest to combine the two
businesses. The Board has convened and has decided to reject the proposal. All
contacts between Meda and Mylan have been terminated without further actions.
The Board’s decision is based on a strong belief in the continued potential of
Meda as a stand-alone company and the assumption that a transaction cannot be
completed as it lacks sufficient support from Meda’s largest shareholder.

The Board of Directors
Meda AB (publ)

For further inquiries, please contact:

Paula Treutiger, Investor
Relations
        ph: +46 733-666 599


                                  paula.treutiger@meda.se

Meda AB discloses the information provided herein pursuant to the Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication on April 28, 2014, at 08:00 CET.

MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in more than 120 countries worldwide and the company is
represented by its own organizations in close to 60 countries. The Meda share is
listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm.
Find out more, visit www.meda.se.